Fig. 7: Anti-cancer effect of PAMT-001 in vivo mouse models.
From: A novel PAAoptosis-inducing ERRα-targeting compound for combating hematopoietic and solid cancers
A, B Subcutaneous growth of HCT-116 cells treated with PAMT-001 (2.18 or 4.36 mg/kg) or vehicle. Tumor volumes were measured with a caliper twice a week. Data are presented as mean ± SD for each day. P-values were calculated using the extra sum of squares F-test. C Schematic diagram of the experiments performed using an orthotropic animal model of AML. D Representative flow cytometry plots showing the engraftment of HL-60 cells with or without PAMT-001 treatment at 4 weeks post-transplantation (left). Irradiated NOD/SCID mice were injected with HL-60 cells (5 × 106 cells per mouse). E Ratio of HL-60 cells (human CD45+ (hCD45+) and murine CD45− (mCD45−)) in the bone marrow. P-values were determined using a two-sided t-test (mean ± SD, n = 4). F NOD/SCID/Il2rg null mice were orthotopically implanted with K562-luc cells (5 × 106 cells/mouse) and administered either a vehicle (PBS) or PAMT-001 (6 mg/kg) seven days post-confirmation of K562-luc cell engraftment. Tumor proliferation was assessed via bioluminescence using the IVIS 200 system. The specified dates denote “days” post-transplantation. G Measurement of luminescent intensity of photons emitted from each tumor in the images presented in (F). P-values were determined using the extra sum of squares F-test. H Change in body weight of NOD/SCID/Il2rg null mice implanted with K562-luc cells upon vehicle or PAMT-001 administration.
